It will become generic in Canada in Q1 of 2026

You're a trad climber! How was it? I climbed in Scotland but it wasn't the greatest (but I love in Squamish, BC, so there's that 😊)

During my time at the KT program as a postdoc, I was sooo appreciative of all the support I got, from my amazing supervisor Dr Tricco, to RAs and support staff. Thanks for all the love!

Sweet, thanks Hilda for the shout out!

Thanks for the shout out!

Here is a look at the overall bias assessment

6/ For those who spend much of their time on systematic reviews, health technology assessment (HTA), evidence synthesis, or reimbursement decision-making, we hope you find this tool to be valuable!

What are your thoughts on improving the evaluation of NMAs? Share freely in the comments below

5/ A systematic framework for assessing whether bias could affect NMA conclusions.

Read the full article here: www.bmj.com/content/388/...

4/ ➡️ For policymakers & guideline developers: Provides confidence that NMA-based recommendations are built on trustworthy evidence

What's in the Paper?
A multi-item tool covering key sources of bias in NMAs

Practical guidance on applying the tool, with real-world examples

3/ How this tool can help:
➡️For researchers: Ensures methodological rigor when conducting and appraising NMAs
➡️For HTA professionals & market access teams: Supports robust evidence evaluation for
reimbursement and coverage decisions

2/ It was a pleasure to be the lead researcher of an international team to develop the ROB NMA tool, published in The BMJ. This tool provides a structured, transparent approach for assessing the risk of bias in NMAS, filling a key gap in the evaluation of comparative effectiveness research